Key facts
- It has raised $1.7M; the latest was Early Stage VC ($580K) in Dec 2025.
- Notable investors include European Rare Diseases Research Alliance, SATT AxLR.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Sitera Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Sitera Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sitera Pharmaceuticals
Developer of small molecule therapeutics intended to address rare and less rare neurodegenerative diseases with urgent patient needs. The company uses a proprietary technological platform that combines chemical and biological expertise to design powerful, selective, and safe drug candidates, focuses on providing clinical solutions for patients who have reached a therapeutic impasse, and targets challenging central nervous system conditions where existing treatment options are limited, enabling healthcare providers to potentially improve life conditions for affected patients.
- Sector
- Healthcare
- HQ
- Montpellier, France
- Founded
- 2025
- Employees
- 2
- Ownership
- Privately Held (backing)
Sitera Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sitera Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sitera Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.